<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:	n/a
For commercial reagents, provide supplier		Not used
name, catalogue number and RRID, if available.		

Cell materials	Yes (indicate where provided:	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		Not used
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	Human adipose stem cells (ASCs) from subcutaneous adipose tissue, male and female, no genetic modification	

Experimental animals	Yes (indicate where provided:	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		Not used
Animal observed in or captured from the field: Provide species, sex and age where possible		Not used
Model organisms: Provide Accession number in repository (where relevant) OR RRID		Not used

Plants and microbes	Yes (indicate where provided:	n/a
Plants: provide species and strain, unique accession		Not used
number if available, and source (including location		
for collected wild specimens)		
Microbes: provide species and strain, unique		Not used
accession number if available, and source		

Human research participants	Yes (indicate where provided:	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number		Not human research
Provide statement confirming informed consent obtained from study participants.		Not human research
Report on age and sex for all study participants.		Not human research

Design

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration		Not clinical
number OR cite DOI in manuscript.		trails
Laboratory protocol	Voc (indicate where provided	n/o
Provide DOI or other citation details if detailed step-	Yes (indicate where provided:	n/a
•	DOI:10.1016/B978-0-12-800280-3.00004-9.	
by-step protocols are available.	DOI:10.1038/nprot.2006.349	
Experimental study design (statistics details)	Yes (indicate where provided:	n/a
State whether and how the following have been		
done , or if they were not carried out.		
Sample size determination	DONE	
Randomisation	DONE	
Blinding	DONE	
Inclusion/exclusion criteria	DONE	
Sample definition and in-laboratory replication	Yes (indicate where provided:	n/a
State number of times the experiment was	3	11/ a
replicated in laboratory	3	
Define whether data describe technical or biological	Technical replicates	
replicates	recrificates	
Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of	www.drks.de (DRKS00009509)	
authority granting ethics approval (IRB or equivalent		
committee(s), provide reference number for		
approval.		
Studies involving experimental animals: State details		Not used
of authority granting ethics approval (IRB or		
equivalent committee(s), provide reference number		
for approval.		
Studies involving specimen and field samples: State if		Not used
relevant permits obtained, provide details of		
authority approving study; if none were required,		
explain why.		
Dual Use Research of Concern (DURC)	Yes (indicate where provided:	n/a
If study is subject to dual use research of concern,	Tes (maisaite where provided)	No
state the authority granting approval and reference		140
state the dathority branching approval and reference	I .	

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is	Abnormal data point was excluded and the criteria	
excluded, and whether the criteria for exclusion were	were determined in advance	
determined and specified in advance.		

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of	Results are expressed as the mean \pm SD and data were	
tests.	analyzed using student's t-test for unpaired samples or the	
	one-way ANOVA for multiple comparisons among	
	groups.	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on	Sent emails to me.	
access.		
If data are publicly available, provide accession number in repository or DOI or URL.		no
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		no

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.	SPSS 20.0(IBM SPSS, Chicago, IL).	
If code is publicly available, provide accession		No code
number in repository, or DOI or URL.		

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article Information: http://dx.doi.org/10.21037/atm-20-7514